BackgroundCheck.run
Search For

Heather Demille Hirsch, 42PO Box 358, Fairport, NY 14450

Known as:
Heather D Hirsch Heather D Foreman Heather Forman
Related to:
Scott M Handy 41

Heather Hirsch Phones & Addresses

Fairport, NY   

Pittsford, NY   

South Dennis, MA   

West Newton, MA   

Thornville, OH   

Columbus, OH   

Cleveland, OH   

Get Report
Control this profile

Mentions for Heather Demille Hirsch

Career records & work history

Lawyers & Attorneys

Heather Hirsch Photo 1

Heather Hirsch - Lawyer

ISLN:
1000864292
Admitted:
2019
Heather Hirsch Photo 2

Heather Hirsch - Lawyer

Office:
Law Offices Tobin • Lucks LLP
Specialties:
Worker's Compensation
ISLN:
921521936
Admitted:
2009
University:
University of California at Los Angeles, B.A.
Law School:
University of La Verne College of Law, J.D., 2009

License Records

Heather Ann Hirsch

Licenses:
License #: 42349 - Expired
Category: Nursing Support
Issued Date: Feb 1, 2000
Effective Date: Mar 31, 2004
Expiration Date: Feb 1, 2003
Type: Medication Aide

Publications & IP owners

Us Patents

Use Of Metformin In Cancer Treatment And Prevention

US Patent:
2012022, Aug 30, 2012
Filed:
Aug 25, 2010
Appl. No.:
13/391890
Inventors:
Kevin Struhl - Weston MA, US
Heather Hirsch - Boston MA, US
Dimitrios Iliopoulos - Brighton MA, US
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE - Cambridge MA
International Classification:
A61K 31/155
A61P 35/00
US Classification:
514635
Abstract:
Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg/day. Also disclosed is a Untreated method for preventing cancer or delaying the recurrence of cancer in a subject comprising administering an effective amount of metformin to the subject. In one example of such a method, the amount of metformin is about 75 mg/day. Also disclosed is a composition comprising an enhancing amount of metformin, and a reduced amount of one or more chemotherapeutic agents and a pharmaceutically acceptable carrier. Kits comprising metformin and one or more chemotherapeutic agents are also disclosed.

Gene Signatures For Determining Icos Expression

US Patent:
2021034, Nov 4, 2021
Filed:
Feb 5, 2021
Appl. No.:
17/168544
Inventors:
- Cambridge MA, US
Igor Feldman - Jamaica Plain MA, US
Christopher Harvey - Boston MA, US
Sriram Sathyanarayanan - Lexington MA, US
Heather Hirsch - Brookline MA, US
Lauren Pepper MacKenzie - Cambridge MA, US
Amit Deshpande - Cambridge MA, US
Stephen Sazinsky - Melrose MA, US
Jennifer S. Michaelson - Brighton MA, US
Kutlu Goksu Elpek - Arlington MA, US
Assignee:
Jounce Therapeutics, Inc. - Cambridge MA
International Classification:
C07K 16/28
C12Q 1/6886
A61P 35/00
A61K 39/00
A61K 39/395
Abstract:
Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Gene Signatures For Determining Icos Expression

US Patent:
2018037, Dec 27, 2018
Filed:
Oct 21, 2016
Appl. No.:
15/767172
Inventors:
- Cambridge MA, US
Igor Feldman - Jamaica Planin MA, US
Christopher Harvey - Boston MA, US
Sriram Sathyanarayanan - Lexington MA, US
Heather Hirsch - Brookline MA, US
Lauren Pepper MacKenzie - Cambridge MA, US
Amit Deshpande - Cambridge MA, US
Stephen Sazinsky - Melrose MA, US
Jennifer S. Michaelson - Brighton MA, US
Kutlu Gosku Elpek - Arlington MA, US
Assignee:
Jounce Therapeutics, Inc. - Cambridge MA
International Classification:
C07K 16/28
C12Q 1/6886
A61P 35/00
Abstract:
Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Predictive Biomarker Useful For Cancer Therapy Mediated By A Cdk Inhibitor

US Patent:
2015005, Feb 19, 2015
Filed:
Mar 27, 2013
Appl. No.:
14/388385
Inventors:
- Rahway NJ, US
Heather A. Hirsch - Brookline MA, US
Leigh Scott Zawel - Weston MA, US
Stephen Eric Fawell - Framingham MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
G01N 33/574
US Classification:
5142593, 506 9, 435 612
Abstract:
The present invention provides a predictive biomarker whose expression level is useful for identifying patients responsive to a therapeutically effective dose of a CDK inhibitor. In one embodiment of the invention, the predictive biomarker is the ratio of MCL-1 to BCL-xL (MCL-1:BCL-xL ratio) and the CDK inhibitor is SCH 927965 (Dinaciclib).

Possible Relatives

Cynthia J Hirsch  David S Hirsch  Dawn M Hirsch  Dean A Hirsch  Dahlia R Hirsch  Deborah S Hirsch  Dana Hirsch  Heather N Johnson  Heather N Standish  Heather L Standley 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.